WallStreetZenWallStreetZen

NASDAQ: TTNP
Titan Pharmaceuticals Inc Stock

$5.67+0.47 (+9.04%)
Updated Jul 17, 2024
TTNP Price
$5.67
Fair Value Price
$5.83
Market Cap
$5.18M
52 Week Low
$4.24
52 Week High
$13.97
P/E
-0.88x
P/B
0.85x
P/S
70.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.00k
Earnings
-$4.95M
Gross Margin
100%
Operating Margin
-5,660.92%
Profit Margin
-5,694.3%
Debt to Equity
0.09
Operating Cash Flow
-$6M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TTNP Overview

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TTNP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TTNP ($5.67) is undervalued by 2.74% relative to our estimate of its Fair Value price of $5.83 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TTNP ($5.67) is not significantly undervalued (2.74%) relative to our estimate of its Fair Value price of $5.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TTNP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TTNP due diligence checks available for Premium users.

Be the first to know about important TTNP news, forecast changes, insider trades & much more!

TTNP News

Valuation

TTNP fair value

Fair Value of TTNP stock based on Discounted Cash Flow (DCF)
Price
$5.67
Fair Value
$5.83
Undervalued by
2.74%
TTNP ($5.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TTNP ($5.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TTNP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TTNP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.88x
Industry
-21.17x
Market
30.24x

TTNP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.85x
Industry
6.35x
TTNP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TTNP's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.1M
Profit Margin
0%
TTNP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TTNP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$6.6M
Liabilities
$559.0k
Debt to equity
0.09
TTNP's short-term assets ($6.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTNP's short-term assets ($6.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTNP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TTNP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$613.0k
Investing
$0.0
Financing
$0.0
TTNP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TTNP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TTNP$5.18M+9.04%-0.88x0.85x
PBM$5.21M-11.39%-38.90x-0.32x
XRTX$5.28M+0.55%-1.83x2.91x
LIXT$5.29M-0.84%-1.01x1.69x
OGEN$5.02M-0.88%-0.13x1.91x

Titan Pharmaceuticals Stock FAQ

What is Titan Pharmaceuticals's quote symbol?

(NASDAQ: TTNP) Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol TTNP. Titan Pharmaceuticals stock quotes can also be displayed as NASDAQ: TTNP.

If you're new to stock investing, here's how to buy Titan Pharmaceuticals stock.

What is the 52 week high and low for Titan Pharmaceuticals (NASDAQ: TTNP)?

(NASDAQ: TTNP) Titan Pharmaceuticals's 52-week high was $13.97, and its 52-week low was $4.24. It is currently -59.41% from its 52-week high and 33.73% from its 52-week low.

How much is Titan Pharmaceuticals stock worth today?

(NASDAQ: TTNP) Titan Pharmaceuticals currently has 914,234 outstanding shares. With Titan Pharmaceuticals stock trading at $5.67 per share, the total value of Titan Pharmaceuticals stock (market capitalization) is $5.18M.

Titan Pharmaceuticals stock was originally listed at a price of $111,876.23 in Dec 31, 1997. If you had invested in Titan Pharmaceuticals stock at $111,876.23, your return over the last 26 years would have been -99.99%, for an annualized return of -31.64% (not including any dividends or dividend reinvestments).

How much is Titan Pharmaceuticals's stock price per share?

(NASDAQ: TTNP) Titan Pharmaceuticals stock price per share is $5.67 today (as of Jul 17, 2024).

What is Titan Pharmaceuticals's Market Cap?

(NASDAQ: TTNP) Titan Pharmaceuticals's market cap is $5.18M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Titan Pharmaceuticals's market cap is calculated by multiplying TTNP's current stock price of $5.67 by TTNP's total outstanding shares of 914,234.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.